Ameriprise
BCAX

Ameriprise’s Bicara Therapeutics BCAX Stock Holding History

Ameriprise’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$315K Sell
15,818
-214
-1% -$3.68K ﹤0.01% 3743
2025
Q4 		$270K Buy
16,032
+50
+0.3% +$854 ﹤0.01% 3834
2025
Q3 		$252K Sell
15,982
-108
-0.7% -$1.21K ﹤0.01% 3843
2025
Q2 		$149K Buy
+16,090
New +$192K ﹤0.01% 3850
2024
Q4 		– Sell
-200,000
Closed -$5.09M – 4172
2024
Q3 		$5.09M Buy
+200,000
New +$5.1M ﹤0.01% 2363

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Ameriprise's BCAX Position: Q1 2026 in Review

Ameriprise reduced its Bicara Therapeutics (BCAX) stake by 1.3% in Q1 2026, selling an estimated $3.68K and leaving 15,818 shares worth $315K. The position accounts for ﹤0.01% of the portfolio, ranked #3743.

Ameriprise first reported a position in BCAX in Q3 2024 and has held it in 5 quarters since. The position peaked at $5.09M in Q3 2024. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • Ameriprise held 15,818 shares of Bicara Therapeutics worth $315K as of Q1 2026.
  • Ameriprise sold 214 Bicara Therapeutics shares in Q1 2026, an estimated $3.68K.
  • Bicara Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #3743 holding.
  • Ameriprise first reported a position in Bicara Therapeutics in Q3 2024 and has held it in 5 quarters since.
  • Ameriprise's Bicara Therapeutics position peaked at $5.09M in Q3 2024.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.